CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,116,004 | -18.5% | 24,587 | +0.7% | 0.33% | -17.0% |
| Q2 2023 | $1,370,097 | +11.8% | 24,405 | -10.0% | 0.40% | +11.7% |
| Q1 2023 | $1,225,869 | +9.0% | 27,103 | -2.0% | 0.36% | +22.1% |
| Q4 2022 | $1,124,460 | -45.3% | 27,662 | -12.1% | 0.29% | -49.1% |
| Q3 2022 | $2,056,000 | -1.6% | 31,467 | -8.5% | 0.58% | -9.8% |
| Q2 2022 | $2,090,000 | +10.6% | 34,387 | +14.2% | 0.64% | +34.4% |
| Q1 2022 | $1,889,000 | -7.3% | 30,105 | +12.0% | 0.48% | -3.8% |
| Q4 2021 | $2,038,000 | -27.6% | 26,889 | +6.9% | 0.50% | -35.8% |
| Q3 2021 | $2,815,000 | -26.4% | 25,147 | +6.4% | 0.77% | -20.2% |
| Q2 2021 | $3,826,000 | +36.9% | 23,636 | +3.0% | 0.97% | +22.7% |
| Q1 2021 | $2,795,000 | +2.2% | 22,942 | +28.4% | 0.79% | -5.7% |
| Q4 2020 | $2,735,000 | – | 17,862 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |